Press Releases Filter Options Archive DateYear20262025202420232022202120202019201820172016201520142013201220112010200920082007MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember View 12 View 12View 24View 48 Categories CorporateFinancialPrescription MedicinesResearch and PipelineSocial ResponsibilityVaccines Keywords All Keywords Covid-19FinanceInvestmentsLeadershipMedicinesPartnershipsResearchResponsibilityVaccines May 2023 05.25.2023 Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19Prescription Medicines September 2022 09.22.2022 Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income CountriesPrescription MedicinesMedicines 09.09.2022 FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia AreataPrescription MedicinesMedicines August 2022 08.05.2022 Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With EndometriosisPrescription MedicinesMedicines June 2022 06.30.2022 Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™Prescription MedicinesMedicines 06.14.2022 Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDAPrescription MedicinesMedicines 06.04.2022 Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast CancerPrescription MedicinesMedicines Page 1 Page 2 Page 3 Page 4 Current page 5
